Rénibus Therapeutics is a privately held clinical-stage biopharmaceutical company headquartered in Southlake, Texas, developing treatments for cardio, renal and metabolic disease. Its pipeline is led by veverimer, a non-absorbed polymer in Phase 3 for metabolic acidosis in chronic kidney disease, and RBT-1 (stannic protoporfin / iron sucrose), a first-in-class intravenous pharmacologic preconditioning agent given 24-48 hours before non-emergent cardiac surgery to reduce post-operative complications, which holds FDA Breakthrough Therapy and Fast Track designations and completed the pivotal Phase 3 PROTECT trial. The company publishes a corporate marketing site, a news and events feed, an expanded access policy and patient information, but operates no developer program, public API, or machine-readable API contract.
Rénibus Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biopharmaceutical, Pharmaceuticals, Life Sciences, and Healthcare.
Rénibus Therapeutics’ developer surface includes engineering blog, support, and 8 more developer resources.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
aid: renibus-therapeutics
name: Rénibus Therapeutics
description: Rénibus Therapeutics is a privately held clinical-stage biopharmaceutical company headquartered in Southlake,
Texas, developing treatments for cardio, renal and metabolic disease. Its pipeline is led by veverimer, a non-absorbed polymer
in Phase 3 for metabolic acidosis in chronic kidney disease, and RBT-1 (stannic protoporfin / iron sucrose), a first-in-class
intravenous pharmacologic preconditioning agent given 24-48 hours before non-emergent cardiac surgery to reduce post-operative
complications, which holds FDA Breakthrough Therapy and Fast Track designations and completed the pivotal Phase 3 PROTECT
trial. The company publishes a corporate marketing site, a news and events feed, an expanded access policy and patient information,
but operates no developer program, public API, or machine-readable API contract.
deliveryModel:
model: saas
open_source: false
commercial: true
callable_host: false
label: Hosted service · you call their endpoint
confidence: medium
source:
- pricing
generated: '2026-08-28'
method: derived
accessModel:
pricing: unknown
onboarding: unknown
trial: false
try_now: false
public: false
label: Unknown
confidence: low
source:
- security
generated: '2026-09-02'
method: derived
image: https://www.renibus.com/wp-content/uploads/2022/10/renibus-therapeutics-logo-retina.png
url: https://raw.githubusercontent.com/api-evangelist/renibus-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.23'
created: '2026-08-05'
modified: '2026-08-05'
tags:
- Company
- Biopharmaceutical
- Pharmaceuticals
- Life Sciences
- Healthcare
- Clinical Trials
- Nephrology
- Cardiovascular
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: Website
url: https://www.renibus.com/
- type: About
url: https://www.renibus.com/about-us/
- type: Blog
url: https://www.renibus.com/news-and-events/
- type: BlogRSS
url: https://www.renibus.com/feed/
- type: Support
url: https://www.renibus.com/contact-us/
- type: PrivacyPolicy
url: https://www.renibus.com/privacy-policy/
- type: TermsOfService
url: https://www.renibus.com/terms-and-conditions/
- type: Careers
url: https://www.renibus.com/careers/
- type: DomainSecurity
url: security/renibus-therapeutics-domain-security.yml
- type: SecondaryMarket
url: https://forgeglobal.com/renibus-therapeutics_stock/
x-enrichment:
date: '2026-08-05'
status: minimal
artifacts_added: 1
pass: local-v1
x-coverage:
state: none
reason: not-a-software-company
detail: Rénibus is a clinical-stage drug developer whose entire public web presence is a ten-page WordPress/Avada marketing
site (about, approach, patients, news, careers, contact, policies) with no developer, docs, or API section; api./developer./docs./portal.renibus.com
do not resolve in DNS and every contract-discovery path returns 404 — the only machine-readable endpoint on the host is
the generic WordPress /wp-json/ CMS route, which is not a product API.
evidence:
- url: https://www.renibus.com/openapi.json
status: 404
- url: https://www.renibus.com/.well-known/agent-card.json
status: 404
- url: https://www.renibus.com/.well-known/security.txt
status: 404
- url: https://www.renibus.com/llms.txt
status: 404
- url: https://www.renibus.com/sitemap.xml
status: 200
checked: '2026-08-05'
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.